About Careers Internship MedBlog Contact us
Promising New Target for Treatment of Psoriasis is Safe

Promising New Target for Treatment of Psoriasis is Safe

Font : A-A+

  • Psoriasis affects more than 1.8 million in the UK alone.
  • Psoriasis is caused by the protein IL-36.
  • IL-36 is a group of inflammatory proteins.

The Protein IL-36 that May Cause Psoriasis
A group of inflammatory proteins called 'IL-36' play a significant role in the development of psoriasis and can, in theory, be blocked without posing a risk to patients. This was confirmed in a study by the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.

The findings of this study, although still at an early stage, open up the possibility for the development of new drugs to tackle this often debilitating condition.


Evidence has emerged during the past several years pointing to a key role for IL-36 in psoriasis. Overexpression of IL-36 in mouse skin leads to a disease quite similar to human plaque psoriasis, and inhibition of IL-36 in human psoriatic skin ameliorates the inflammation. Loss of the natural antagonist of IL-36, IL-36Ra, results in a different, more severe skin disease known as pustular psoriasis. These effects are likely a consequence of the actions of IL-36 both on cells of the immune system as well as on components of skin including fibroblasts and keratinocytes.

Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales and affects more than 1.8 million in the UK alone.

Is Blocking of the Psoriasis Causing Protein Safe?
The protein known to play a significant role in the development of psoriasis can be prevented from functioning without posing a risk to patients, scientists at King's College London have found.

Dr. Francesca Capon, who led the study at King's College London said: "There was already some evidence to suggest that IL-36 played a significant role in psoriasis. Having confirmed this was the case, the question for us was whether we could block this molecule without posing a risk to patients."

To tackle this problem, Dr. Capon and her team contacted the Born in Bradford (BiB) project, a large study led by Prof John Wright at Bradford Royal Infirmary which is tracking the health of over 13,500 local children and their parents.

"We know that genetic mutations are more common in communities where parental relatedness is widespread and we found 12 women in the BiB cohort who carried a defect that naturally blocked IL-36," said Dr. Capon. "After a series of tests carried out by Dr Satveer Mahil at St John's Institute of Dermatology, we determined that the lack of IL-36 activation had not had an adverse effect on their health which suggests it would be safe to block this molecule in patients with psoriasis."

Medical technology which would enable the blocking of IL-36 group of inflammatory proteins in patients with psoriasis is already widely available.

Helen McAteer, Chief Executive of the Psoriasis Association, which part-funded the study, said: "Research into psoriasis is enabling us to not only understand the condition better, but the treatments better".

"Current research is having a positive impact on clinical effectiveness, better understanding is providing better treatment outcomes, ultimately improving the lives of those affected by psoriasis."

  1. Satveer K. Mahil and Marika Catapano et al. An Analysis of Il-36 Signature Genes and Individuals with Il1Rl2 Knockout Mutations Validates Il-36 as a Psoriasis Therapeutic Target, Science Translation Medicinehttp:stm.sciencemag.org/content/9/411/eaan2514

Source: Eurekalert

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chrisy Ngilneii. (2017, October 13). Promising New Target for Treatment of Psoriasis is Safe. Medindia. Retrieved on Sep 25, 2022 from https://www.medindia.net/news/healthwatch/promising-new-target-for-treatment-of-psoriasis-is-safe-173758-1.htm.

  • MLA

    Chrisy Ngilneii. "Promising New Target for Treatment of Psoriasis is Safe". Medindia. Sep 25, 2022. <https://www.medindia.net/news/healthwatch/promising-new-target-for-treatment-of-psoriasis-is-safe-173758-1.htm>.

  • Chicago

    Chrisy Ngilneii. "Promising New Target for Treatment of Psoriasis is Safe". Medindia. https://www.medindia.net/news/healthwatch/promising-new-target-for-treatment-of-psoriasis-is-safe-173758-1.htm. (accessed Sep 25, 2022).

  • Harvard

    Chrisy Ngilneii. 2021. Promising New Target for Treatment of Psoriasis is Safe. Medindia, viewed Sep 25, 2022, https://www.medindia.net/news/healthwatch/promising-new-target-for-treatment-of-psoriasis-is-safe-173758-1.htm.


News A-Z
What's New on Medindia
Test Your Knowledge About Chromosomes?
Eating During Sunlight Hours Minimizes Mood Vulnerabilities
Know More About the Digestive System
View all
Recommended Reading
News Archive
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Psoriasis Dry Skin Symptom Evaluation Foods that are Bad for your Skin Itchy Scalp Diet for Psoriasis Scalp Psoriasis Psoriasis Cure with Homeopathy: Fact or Fiction Psoriatic Arthritis 

Most Popular on Medindia

Turmeric Powder - Health Benefits, Uses & Side Effects Selfie Addiction Calculator Find a Hospital Blood Donation - Recipients Calculate Ideal Weight for Infants Sanatogen Drug - Food Interactions The Essence of Yoga Blood Pressure Calculator Hearing Loss Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close


Promising New Target for Treatment of Psoriasis is Safe Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests